Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc., a leading biopharmaceutical company based in the United States, focuses on developing innovative therapies for men’s health, particularly in hormone replacement. Founded in 2009, Clarus has made significant strides in the industry, notably with its flagship product, Jatenzo, which offers a unique oral testosterone replacement option, setting it apart from traditional injectable therapies. Headquartered in the US, Clarus operates primarily in North America, aiming to address the unmet needs of patients with testosterone deficiency. The company has established a strong market position, recognised for its commitment to advancing men's health through research and development. With a focus on patient-centric solutions, Clarus Therapeutics continues to drive innovation in the biopharmaceutical sector, contributing to improved quality of life for men facing hormonal challenges.
DitchCarbon Score
How does Clarus Therapeutics Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Clarus Therapeutics Holdings, Inc.'s score of 18 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Clarus Therapeutics Holdings, Inc.'s reported carbon emissions
Clarus Therapeutics Holdings, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for recent years, as indicated by the absence of specific emissions figures. Furthermore, there are no documented reduction targets or climate pledges outlined by the company. This lack of information suggests that Clarus Therapeutics may still be in the early stages of developing a comprehensive climate strategy or reporting framework. As the industry increasingly prioritises sustainability, it will be essential for Clarus Therapeutics to establish clear commitments and measurable targets to align with global climate goals and enhance its environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Clarus Therapeutics Holdings, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
